Business
Patents Granted
Patents Granted.
About this update from Immupharma Plc
[{"type":"text","content":"\n RNS Number : 3059G Immupharma PLC 21 October 2008 \n \nFor Immediate Release 21 October 2008\n\n\nLupuzorTM patents allowed in US and approved in Japan, Australia\n- other countries expected to follow -\n\n\nImmuPharma PLC (LSE:IMM), ('ImmuPharma or the 'Company') the specialist drug discovery and development company, is pleased to announce that the LupuzorTM patent was approved in Japan and Australia and received notice of allowance from in the US Patent Office. LupuzorTM is ImmuPharma's lead drug compound for the potential treatment of Lupus, a chronic, life-threatening autoimmune disease.\n\n\nIn addition, the mechanism of action of LupuzorTM has been identified by researchers working with ImmuPharma at the Centre National de la Recherche Scientifique in Strasbourg. LupuzorTM has shown that it modulates, through a unique mechanism, a specific subset of CD4 T cells which play a critical role in the physiopathology of Lupus. A new patent which covers this discovery is being filed. This mechanism is consistent with and explains the very favourable safety profile of LupuzorTM (maintenance of the overall immune system while being effective) and its activity as a specific immune-modulator.\n\nDr. Robert Zimmer, President & Chief Scientific Officer said: 'The recent progress on the patents of LupuzorTM are a key milestone in the Company's efforts to bring an innovative drug candidate for treating patients suffering from Lupus. . Importantly the mechanism of action of LupuzorTM has been identified, providing further confidence in its development.' \n\nFor further information please contact: \n\nImmuPharma PLC: \nDimitri Dimitriou, Chief Executive Officer &nbs...